Progress in Cardiovascular Diseases Progress in Cardiovascular Diseases RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Masthead
(Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - August 31, 2016 Category: Cardiology Source Type: research

Table of Contents
(Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - August 31, 2016 Category: Cardiology Source Type: research

List of Recent Issues
(Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - August 31, 2016 Category: Cardiology Source Type: research

Editorial Board
(Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - August 31, 2016 Category: Cardiology Source Type: research

Analyzing 2015 Impact Factors – Special Editor's Commentary
In June, 2016, the new 2015 Journal Impact Factors (IF) were released, which is based on papers published in 2013 and 2014 and citations during 2015. As noted in Table 1, the IF for Progress in Cardiovascular Diseases (PCVD) increased from the mid 2 ’s the prior two years to now 4.635, increasing the PCVD rankings from 55th of 123 cardiovascular (CV) Journals in 2014 to now 21st of 124 CV Journals. This is the first time since 2011 that PCVD has been back in the Top 25 list of CV Journals (Table 2). (Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - August 27, 2016 Category: Cardiology Authors: Carl J. Lavie Tags: Editorial Source Type: research

Diagnosis and treatment of high density lipoprotein deficiency
Low serum high density lipoprotein cholesterol level (HDL-C) (Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - August 22, 2016 Category: Cardiology Authors: Ernst J. Schaefer, Pimjai Anthanont, Margaret R. Diffenderfer, Eliana Polisecki, Bela F. Asztalos Source Type: research

The P4 Health Spectrum – A Predictive, Preventive, Personalized and Participatory Continuum for Promoting Healthspan
Chronic diseases (i.e., Noncommunicable Diseases), mainly cardiovascular disease, cancer, respiratory diseases and type-2-diabetes, are now the leading cause of death, disability and diminished quality of life on the planet. Moreover, these diseases are also a major financial burden worldwide, significantly impacting the economy of many countries. Healthcare systems and medicine have progressively improved upon the ability to address infectious diseases and react to adverse health events through both surgical interventions and pharmacology; we have become efficient in delivering reactive care (i.e., initiating intervention...
Source: Progress in Cardiovascular Diseases - August 17, 2016 Category: Cardiology Authors: Michael Sagner, Amy McNeil, Pekka Puska, Charles Auffray, Nathan D. Price, Leroy Hood, Carl J. Lavie, Ze-Guang Han, Zhu Chen, Samir Kumar Brahmachari, Bruce S. McEwen, Marcelo B. Soares, Rudi Balling, Elissa Epel, Ross Arena Source Type: research

New Eyes on Lipids and Lipoproteins
"The real voyage of discovery consists of not in seeking new landscapes but in having new eyes."- Marcel Proust (Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - August 17, 2016 Category: Cardiology Authors: Neil J. Stone, Conrad B. Blum Tags: Editorial Source Type: research

Triglyceride Treatment in the Age of Cholesterol Reduction
Cholesterol reduction has markedly reduced major cardiovascular disease (CVD) events and shown regression of atherosclerosis in some studies. However, CVD has for decades also been associated with increased levels of circulating triglyceride (TG)-rich lipoproteins. Whether this is due to a direct toxic effect of these lipoproteins on arteries or whether this is merely an association is unresolved. More recent genetic analyses have linked genes that modulate TG metabolism with CVD. Moreover, analyses of subgroups of hypertriglyceridemic (HTG) subjects in clinical trials using fibric acid drugs have been interpreted as evide...
Source: Progress in Cardiovascular Diseases - August 17, 2016 Category: Cardiology Authors: Nidhi Agrawal, Patricia Freitas Corradi, Namrata Gumaste, Ira J. Goldberg Source Type: research

Cardiac Rehabilitation Delivery Model for Low-Resource Settings: An International Council of Cardiovascular Prevention and Rehabilitation Consensus Statement
Cardiovascular disease (CVD) is a global epidemic, which is largely preventable. Cardiac rehabilitation (CR) is demonstrated to be efficacious and cost-effective for secondary prevention in high-income countries. Given its affordability, CR should be more broadly implemented in middle-income countries as well. Hence, the International Council of Cardiovascular Prevention and Rehabilitation (ICCPR) convened a writing panel to recommend strategies to deliver all core CR components in low-resource settings, namely: (1) initial assessment, (2) lifestyle risk factor management (i.e., diet, tobacco, mental health), (3) medical r...
Source: Progress in Cardiovascular Diseases - August 17, 2016 Category: Cardiology Authors: Sherry L. Grace, Karam I. Turk-Adawi, Aashish Contractor, Alison Atrey, Norman R.C. Campbell, Wayne Derman, Gabriela L.M. Ghisi, Bidyut K. Sarkar, Tee J. Yeo, Francisco Lopez-Jimenez, John Buckley, Dayi Hu, Nizal Sarrafzadegan Source Type: research

The Risk of Hepatotoxicity, New Onset Diabetes and Rhabdomyolysis in the Era of High-Intensity Statin Therapy: Does Statin Type Matter?
The 2013 American College of Cardiology/American Heart Association guidelines on cholesterol management have placed greater emphasis on high-intensity statin dosing for those with known cardiovascular disease or diabetes mellitus. Differences in risk of hepatotoxicity, new onset DM and rhabdomyolysis specifically between the high-intensity statins and the most common moderate-intensity statin, simvastatin, were not found to a significant degree in this review. Rather, baseline characteristics and drug –drug interactions (DDIs) appear to be more important regarding the risk of these adverse effects. (Source: Progress in C...
Source: Progress in Cardiovascular Diseases - August 4, 2016 Category: Cardiology Authors: Lane B. Benes, Nikhil S. Bassi, Michael H. Davidson Source Type: research

Nonstatins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Role in Non ‐Familial Hypercholesterolemia
After maximizing statin and lifestyle adherence, some patients may benefit from additional low-density lipoprotein cholesterol (LDL-C) lowering. The potential for net benefit from added therapy can inform nonstatin decision-making. Considering patient risk and the LDL-C level on statin, the additional potential cardiovascular disease (CVD) risk reduction benefit from further lowering LDL-C depends on the magnitude of LDL-C lowering from the nonstatin. Ezetimibe is the only nonstatin shown to reduce atherosclerotic CVD events added to a statin, albeit modestly, since it modestly reduces LDL-C by about 20%. (Source: Progress...
Source: Progress in Cardiovascular Diseases - August 3, 2016 Category: Cardiology Authors: Jennifer G. Robinson Source Type: research

Nonstatins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Role in Non-Familial Hypercholesterolemia
After maximizing statin and lifestyle adherence, some patients may benefit from additional low-density lipoprotein cholesterol (LDL-C) lowering. The potential for net benefit from added therapy can inform nonstatin decision-making. Considering patient risk and the LDL-C level on statin, the additional potential cardiovascular disease (CVD)risk reduction benefit from further lowering LDL-C depends on the magnitude of LDL-C lowering from the nonstatin. Ezetimibe is the only nonstatin shown to reduce atherosclerotic CVD events added to a statin, albeit modestly, since it modestly reduces LDL-C by about 20%. (Source: Progress ...
Source: Progress in Cardiovascular Diseases - August 3, 2016 Category: Cardiology Authors: Jennifer G. Robinson Source Type: research

Metabolic Syndrome: An Evolving Clinical Construct
Metabolic syndrome (MetS), a clustering of metabolic risk factors, identifies individuals at increased risk of diabetes and cardiovascular disease (CVD). Measurement of waist circumference, high-density lipoprotein-cholesterol, triglycerides, blood pressure and fasting blood glucose are easily obtained in the clinic. At any level of low-density lipoprotein-cholesterol, presence of MetS increases the risk of adverse CVD outcomes including both atherosclerotic CVD and atrial fibrillation. The MetS construct should focus the clinician on recommending behavioral lifestyle modification as this improves all of its components. (S...
Source: Progress in Cardiovascular Diseases - August 3, 2016 Category: Cardiology Authors: Patricia Vassallo, Steven L. Driver, Neil J. Stone Source Type: research

Cholesterol Guidelines: More Similar Than Different
A clinician has a large number of guidelines to follow. Searching the words “cardiovascular” and “guideline” on the website, www.guideline.gov yielded 502 cardiovascular guidelines, 40 alone in 2015. 1 [National Guideline Clearinghouse: Agency for Healthcare Research and 19 Quality (n.d.)] Similarly, searching the words “cholesterol” and “guideline” yielded 107 results, 6 alone in 2015. This information overload can decrease providers' self-efficacy in using guidelines, particularly if they have inconsistent messages. (Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - August 2, 2016 Category: Cardiology Authors: Yashashwi Pokharel, Julia M. Akeroyd, Salim S. Virani Source Type: research